ARQTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Arcutis Biotherapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$31.89+3.07 (+10.65%)
Close on Oct 19, 2026
- Market cap
- $4.33B
- P/E (TTM)
- 145.0
- Dividend yield
- –
Arcutis Biotherapeutics, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- 91.1%
- Operating margin
- 7.4%
- Net margin
- 6.1%
- Return on equity, FY2025
- -9.3%
Financial strength
- Current ratio
- 2.92
- Debt to equity
- 0.49
- Debt to assets
- 22.3%
- Cash to current liabilities
- 21.3%
Valuation
- P/E ratio
- 145.0
- Price to sales
- 9.34
- Price to book
- 19.65
- Dividend yield
- –